Elastic NV vs NeoGenomics Inc. Common Stock — how do they compare? Elastic NV trades at $90.77 (market cap $9.67B), while NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B). The key difference: Elastic NV is far larger — about 4.5× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is more actively traded (1,615,943 versus 1,592,425). Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 11 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| ESTC | NEO | |
|---|---|---|
Market Cap | $9.67B | $2.17B |
Volume | 1,592,425 | 1,615,943 |
Sector | Technology | Health |
52-Week High | $99.91 | $19.91 |
52-Week Low | $43.30 | $7.19 |
Typical Hold Time | 11 Days | 0 Days |
Enterprise Value | $8.80B | $2.47B |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $94.32, down 1.26% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent product launches, including a metrics platform and serverless vector database, highlight innovation in AI and data search. Revenue grew to $1.48 billion in 2025, with a projected increase to $1.8 billion in 2026, though 2025 net income was negative.
The outlook is positive, driven by product innovation and earnings beats, but high valuation ratios and negative net income in 2025 pose risks. Analyst consensus is bullish with a $83.18 price target, suggesting potential upside. Key risks include execution challenges and competitive pressures in the software sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →